Latest Current Report
Filed: 2026-05-04
Key Insights
- Hemab Therapeutics completed its IPO on May 4, 2026, raising $346.7 million in gross proceeds at $18.00 per share, including full exercise of underwriter options for 19.3 million shares.
- The company implemented anti-takeover protections including a classified board with staggered three-year terms, 75% supermajority vote requirement for director removal, and elimination of stockholder written consent rights.
- The Restated Certificate authorizes 400 million common shares and 5 million undesignated preferred shares, significantly increasing capital structure flexibility post-IPO.
- Delaware Court of Chancery is designated as exclusive forum for internal corporate claims, while federal courts handle securities law claims, limiting stockholder litigation venue options.